New trials, publications, preprints and grants on this target, month by month.
Trial
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
1 Dec 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Coexistence of ARNT::ALK and TPM3::ALK doublegene fusion in an ALK-rearranged renal cell carcinoma with osseous metaplasia.
4 Nov 2026· American journal of clinical pathology· PUBMED
Publication
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2 Nov 2026· Cancer discovery· PUBMED
Publication
Distinct prognostic role of ALK fusion in early and advanced-stage lung adenocarcinoma stratified by clinicopathologic and radiologic features.
2 Nov 2026· Chinese medical journal· PUBMED
Trial
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Diffuse Eruptive Spitz Nevus With Somatic TPM3::ALK Fusion Confirmed Across Anatomically Distinct Lesions.
1 Nov 2026· Pigment cell & melanoma research· PUBMED
Publication
Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer. Reply.
29 Oct 2026· The New England journal of medicine· PUBMED
Publication
Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer.
29 Oct 2026· The New England journal of medicine· PUBMED
Publication
Lorlatinib-Containing Therapy for MYCN-Amplified, ALK-Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report.
29 Oct 2026· Pediatric blood & cancer· PUBMED
Publication
Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer.
26 Oct 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
ASO Visual Abstract: Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma-A Multicenter CReGYT-03 ALK Study.
23 Oct 2026· Annals of surgical oncology· PUBMED
Publication
Comment on "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis".
23 Oct 2026· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publication
[Expert consensus on iruplinalkib for the treatment of ALK fusion gene positive non-small cell lung cancer (2026 edition)].
23 Oct 2026· Zhonghua zhong liu za zhi [Chinese journal of oncology]· PUBMED
Publication
Comment on: "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis": Toward risk-adapted adjuvant therapy beyond ALINA.
21 Oct 2026· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publication
ASO Author Reflections: Rethinking Adjuvant Chemotherapy in Resected ALK-Positive Lung Cancer.
19 Oct 2026· Annals of surgical oncology· PUBMED
Publication
Comment on "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis": ALK ascertainment and the interpretation of a null result.
15 Oct 2026· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publication
Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting.
14 Oct 2026· Clinical lung cancer· PUBMED
Publication
A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer.
14 Oct 2026· Future oncology (London, England)· PUBMED
Publication
Clinical and radiographic improvement in suspected pulmonary lymphangitic carcinomatosis-associated hypoxemic respiratory failure following iruplinalkib-based treatment in ALK-positive lung adenocarcinoma after sequential treatment with ensartinib and lorlatinib: a two-patient case report.
13 Oct 2026· Frontiers in medicine· PUBMED
Publication
Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
12 Oct 2026· Current oncology (Toronto, Ont.)· PUBMED
Publication
EML4-ALK fusion rewires transcriptomic, miRNA, and CAF-associated programs in non-small cell lung cancer.
9 Oct 2026· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publication
Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study.
9 Oct 2026· Lung cancer (Amsterdam, Netherlands)· PUBMED
Publication
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).
8 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Subdural Hematoma During Lorlatinib-Induced Regression of Leptomeningeal Carcinomatosis with Suspected Dural Involvement in ALK-Positive Lung Adenocarcinoma.
8 Oct 2026· Internal medicine (Tokyo, Japan)· PUBMED
Publication
Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis.
7 Oct 2026· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publication
Real-world evolution of first-line ALK-positive NSCLC management in Spain.
6 Oct 2026· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publication
Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.
5 Oct 2026· Annals of surgical oncology· PUBMED
Publication
Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study.
4 Oct 2026· MedComm· PUBMED
Publication
A Narrative Review of the Cases of Co-altered EGFR and ALK in Non-small Cell Lung Cancers: An Attempt to Break the Therapeutic Dilemma.
4 Oct 2026· Cureus· PUBMED